证券代码：002900 证券简称：哈三联 公告编号：2025-065 哈尔滨三联药业股份有限公司 关于聘任 2025 年度会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、中兴财光华会计师事务所（特殊普通合伙）（以下简称"中兴财光 华"）对公司 2024 年度财务报告出具了标准无保留意见的审计报告（中兴 财光华审会字（2025）第 213118 号）。 2、拟聘任的会计师事务所名称：上会会计师事务所（特殊普通合伙）。 4、聘任原因：中兴财光华与公司签订的审计服务合同已到期，为充分 保障公司审计工作安排，更好地适应公司未来业务发展，综合考虑市场信 息，基于审慎性原则以及公司对审计服务的需求，按照《国有企业、上市 公司选聘会计师事务所管理办法》等有关规定，公司通过邀请招标的方式 聘请上会会计师事务所（特殊普通合伙）担任公司 2025 年度财务、内控审 计机构。 5、公司聘任会计师事务所符合财政部、国务院国资委、证监会印发的 《国有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号） 的规定。 6、本次聘任会计师事务所 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-068 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"或"哈三联"）于 2025 年 10 月 23 日召开第四届董事会第二十六次会议，审议通过了《关于聘任 2025 年度会 计师事务所的议案》，上述议案须提交公司股东大会审议。 为提高会议决策效率、降低会议成本，公司第四届董事会第二十六次会议决 定暂不召开股东大会审议上述事项。后期公司董事会将根据整体工作安排，另行 发布召开股东大会的通知，提请股东大会审议相关议案。 特此公告。 哈尔滨三联药业股份有限公司 哈尔滨三联药业股份有限公司 关于暂时不召开股东大会的公告 2025年10月23日 1 董事会 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-063 哈尔滨三联药业股份有限公司 第四届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届监事会第二 十一次会议于 2025 年 10 月 21 日以电子邮件及微信形式向全体监事发出通知。 2、本次会议于 2025 年 10 月 23 日在公司会议室以现场表决方式召开。 3、本次会议应出席监事 3 人，实际出席会议并表决的监事 3 人。 4、公司监事会主席翟玉平先生主持本次会议。 二、监事会会议审议情况 会议审议通过了以下议案： 1、审议通过《关于 2025 年第三季度报告的议案》 经审核，监事会认为董事会编制和审议公司 2025 年第三季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决情况：有效表决 3 票，同意 3 票，反对 0 票，弃权 0 票； 表决结果：通过。 2、审议通过 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-062 第四届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届董事会第二 十六次会议于 2025 年 10 月 21 日以电子邮件及微信形式向全体董事发出通知。 2、本次会议于 2025 年 10 月 23 日以通讯表决的方式召开。 3、本次会议应出席董事 9 人，实际出席会议并表决的董事 9 人。 哈尔滨三联药业股份有限公司 4、公司董事长秦剑飞先生主持本次会议，公司监事、总裁及董事会秘书列 席会议。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、董事会会议审议情况 会议审议并通过以下议案： 1、审议通过《关于 2025 年第三季度报告的议案》 表决情况：有效表决 9 票，同意 9 票，反对 0 票，弃权 0 票 表决结果：通过 本议案已经第四届董事会审计委员会 2025 年第四次 ...

哈尔滨三联药业股份有限公司 表决结果：通过。 二、审议通过《关于拟参与竞拍资产暨关联交易的议案》 经核查，公司本次拟参与竞拍有助于推动公司产业布局的全面发展，同时充 分发挥业务的协同性，符合公司发展需要，不存在损害公司及全体股东特别是中 小股东利益的情形。会议的表决程序符合《公司法》《证券法》等有关法律法规 和《公司章程》的规定。同意将该议案提交董事会审议。 第四届董事会 2025 年第四次 独立董事专门会议决议的公告 哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会 2025 年第 四次独立董事专门会议于 2025 年 10 月 21 日以电子邮件、微信形式向全体独立 董事发出通知，于 2025 年 10 月 21 日以通讯方式召开。会议应出席独立董事 3 人，实际出席的独立董事 3 人。本次会议的通知、召集和召开程序符合法律、法 规及《公司章程》、《独立董事工作制度》的相关规定，会议由独立董事王栋先 生召集并主持，经与会独立董事讨论，形成会议决议如下： 一、审议通过《关于独立董事专门会议豁免提前通知的议案》 全体独立董事一致同意豁免本次会议提前 3 日通知的时限要求，同意于 2025 年 10 ...

Financial Performance - The company's revenue for Q3 2025 was ¥167,526,697.03, a decrease of 46.83% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥116,451,164.25, representing a decline of 913.69% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥121,245,126.35, down 1,113.19% from the previous year[5]. - Total operating revenue for the current period was CNY 580,649,067.87, a decrease of 30.8% compared to CNY 838,525,846.47 in the previous period[19]. - The net profit for the current period was a loss of CNY 211,476,435.44, compared to a profit of CNY 37,498,969.48 in the previous period[19]. - The total comprehensive income amounted to -211,476,435.44 CNY, down from 37,498,969.48 CNY in the prior period[20]. - The basic and diluted earnings per share were both -0.66 CNY, compared to 0.13 CNY in the previous period[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,609,272,790.67, a decrease of 5.03% from the end of the previous year[5]. - Current assets totaled CNY 1,187,835,221.22, down from CNY 1,471,966,906.93, indicating a decrease of 19.3%[16]. - Non-current assets increased to CNY 2,421,437,569.45 from CNY 2,328,501,363.24, representing a growth of 4.0%[17]. - Total liabilities rose to CNY 1,704,282,058.15 from CNY 1,636,313,285.80, an increase of 4.1%[18]. - The total owner's equity decreased to CNY 1,904,990,732.52 from CNY 2,164,154,984.37, a decline of 12.0%[18]. Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥27,645,727.39, up 161.27% year-to-date[5]. - Cash flow from operating activities generated a net inflow of 27,645,727.39 CNY, a recovery from a net outflow of -45,120,146.94 CNY in the prior period[22]. - Cash inflow from investment activities was 144,266,659.10 CNY, down from 225,785,193.74 CNY in the previous period[22]. - Cash outflow from investment activities totaled 316,908,290.76 CNY, compared to 504,051,443.94 CNY in the prior period[22]. - Cash flow from financing activities generated a net inflow of 231,513,898.50 CNY, compared to 304,959,417.97 CNY in the previous period[22]. - The ending cash and cash equivalents balance was 641,999,568.80 CNY, up from 523,931,302.90 CNY in the prior period[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,527, with no preferred shareholders[12]. - The largest shareholder, Qin Jianfei, holds 39.10% of shares, totaling 123,705,000 shares, with 21,000,000 shares pledged[13]. Expenses and Income - The company’s financial expenses surged by 3,555.24% to ¥12,782,675.20, primarily due to a decrease in interest income and loan subsidies[9]. - The investment income decreased by 34.75% to ¥16,629,941.00, attributed to reduced earnings from affiliated companies[9]. - The company’s public value change loss was -¥9,770,148.86, reflecting a further decline in the fair value of securities investments[9]. - Credit impairment losses increased by 783.77% to CNY 1,754,410.33 due to a decrease in receivables and the reversal of bad debt provisions[10]. - Asset impairment losses decreased by 4,378.31% to CNY -53,955,391.28, primarily due to significant declines in product prices and large inventory write-downs[10]. - Cash received from government subsidies related to operating activities increased by 55.94% to CNY 87,080,270.16, reflecting higher deferred income from government support[10]. - Cash received from investment income rose by 40.05% to CNY 29,082,226.10, attributed to increased dividends from long-term equity investments[10]. - Cash paid for fixed assets and intangible assets decreased by 43.05% to CNY 146,908,290.76, indicating reduced project investments during the reporting period[10]. - The company reported a significant decrease in other operating expenses, down 95.77% to CNY 58,206.03, compared to the previous year[10]. - The company paid 202,613,824.39 CNY in employee compensation, down from 230,107,253.43 CNY in the prior period[22].

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.32% on October 22, with Dize Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Xiangdi Pharmaceutical (301211) with a closing price of 14.99, up 14.25% [1] - Duorui Pharmaceutical (301075) at 58.62, up 10.21% [1] - Guangji Pharmaceutical (000952) at 7.77, up 10.06% [1] - Hasi Lian (002900) at 14.61, up 10.02% [1] - Yatai Pharmaceutical (002370) at 7.70, up 10.00% [1] - Dize Pharmaceutical (688192) was the biggest loser, closing at 60.11, down 6.20% [2] - Other significant decliners included: - Kangzhiyue Pharmaceutical (300086) down 5.90% [2] - Puluo Pharmaceutical (000739) down 5.41% [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 185 million yuan from institutional investors, while retail investors experienced a net inflow of 41.4 million yuan [2] - However, speculative funds recorded a net outflow of 227 million yuan [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Yatai Pharmaceutical (002370) with a net inflow of 2.38 billion yuan from institutional investors, but a net outflow of 95.28 million yuan from speculative funds [3] - Anglikang (002940) had a net inflow of 182 million yuan from institutional investors, with a net outflow of 97.14 million yuan from speculative funds [3] - Hasi Lian (002900) recorded a net inflow of 117 million yuan from institutional investors, but a significant net outflow of 59.36 million yuan from speculative funds [3]

Market Overview - The Shanghai Composite Index is at 3907.95 points, slightly down by 0.21%, and is above the five-day moving average [1] - The total trading volume of A-shares today is 137.8 billion yuan [1] Stocks Performance - A total of 537 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Wanda Bearings with a deviation rate of 9.53% and a daily increase of 12.27% [1] - Electric Wind Power with a deviation rate of 9.42% and a daily increase of 13.35% [1] - Tianwo Technology with a deviation rate of 8.10% and a daily increase of 10.00% [1] Detailed Stock Data - The following stocks have notable performance metrics: - Wanda Bearings (Code: 920002): Latest price 115.99 yuan, five-day moving average 105.89 yuan, daily turnover rate 9.75% [1] - Electric Wind Power (Code: 688660): Latest price 22.08 yuan, five-day moving average 20.18 yuan, daily turnover rate 3.60% [1] - Tianwo Technology (Code: 002564): Latest price 9.02 yuan, five-day moving average 8.34 yuan, daily turnover rate 5.08% [1]

Core Viewpoint - The article highlights a significant surge in the innovative drug sector, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, which could lead to a total transaction value of up to $11.4 billion (approximately 81.2 billion RMB) [3][5]. Group 1: Market Performance - On October 22, A-shares and Hong Kong stocks related to innovative drugs experienced a strong rally, with several stocks like Innovent Biologics and Haisco Pharmaceutical hitting the daily limit [4]. - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [6]. Group 2: Strategic Collaboration - Innovent Biologics announced a global strategic partnership with Takeda to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [4][6]. - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with Takeda leading the global development and commercialization efforts outside of Greater China and the U.S. [4][5]. Group 3: Financial Implications - Innovent Biologics will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and could earn up to $10.2 billion in potential milestone payments [5]. - The partnership is expected to significantly enhance Takeda's oncology pipeline, which has faced challenges in recent years [6]. Group 4: Industry Trends - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [7]. - The fourth quarter is anticipated to see an acceleration in business development (BD) activities, with major pharmaceutical companies likely to allocate their annual budgets during this period [8].

Core Viewpoint - The pharmaceutical sector has experienced significant stock price increases, with Hendi Pharmaceutical reaching a 20% limit-up, and several other companies also showing substantial gains [1] Group 1: Company Performance - Hendi Pharmaceutical's stock surged by 20%, hitting the daily limit [1] - Duori Pharmaceutical's stock rose by over 13% [1] - Other companies such as Guangji Pharmaceutical, Te Yi Pharmaceutical, Hasan Lian, and Chenxin Pharmaceutical also reached their daily limit [1]